ArticleJournal of cellular and molecular medicine2025
Impact of SPP1 and HMOX1 Genes in Glioma: Correlations With Oncolytic Virus Infection, Adverse Prognosis and Increased Cell Proliferation.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosome-mediated miR-4660 delivery inhibits OPN promoted hepatoma cells aggression through targeting LGALS3BP.Journal of cell communication and signaling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A high death rate among glioma patients is primarily due to poor prognostic outcomes and tumour metastasis. Oncolytic viruses have gained attention as a potential therapeutic strategy as eliminating tumour cells and modifying tumour microenvironment. This research highlights the urgent necessity to investigate novel therapeutic targets and clarify molecular mechanisms in glioma. The GSE166914 dataset was analysed to examine the SPP1 and HMOX1 expression after VSV-M51 infection in glioma. By utilising the CancerSEA database, we assessed the potential function of SPP1/HMOX1 among pan-cancer. Analysis of gene/protein expression levels and clinical significance was performed to identify the roles of SPP1/HMOX1 using TCGA-glioma data. A correlation analysis was performed to screen co-expressed genes, followed by GSEA analysis. qPCR and HPA analysis were utilised to assess the mRNA/protein levels of SPP1 and HMOX1 in glioma tissues. The anti-apoptotic activity of SPP1 and HMOX1 was confirmed utilising the CCK-8 assay and flow cytometry. VSV-M51 infection resulted in SPP1/HMOX1 downregulation in T98 cells. The expression levels of SPP1/HMOX1 were significantly increased in glioma and associated with histological classifications and WHO grades. Elevated levels of SPP1/HMOX1 were related to poor prognosis in glioma. SPP1/HMOX1 was involved in influencing glioma cell motility through the PI3K/AKT, JAK-STAT and syndecan 1 signalling pathways. In vitro experiments showed higher expression levels of SPP1/HMOX1 in glioma tissues. Silencing SPP1/HMOX1 suppressed glioma cell proliferation and promoted apoptosis. In conclusion, dysregulated SPP1/HMOX1 expression was strongly related to glioma WHO grades and worse outcomes, providing deeper insights into glioma therapeutic targets and oncolytic virus-based treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.